Genoway (ALGEN.PA) Stock Price
Genoway Price
Revenue has compounded at 9.9% per year over the past 19 years to 20.96 M EUR. Earnings per share have grown at 8.6% per year over the last 16 years. Genoway's net margin stands at 4.4%, up from -2.3% several years earlier. Analysts set a median price target of 6.02 EUR, implying 142.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 18% above its 52-week low.
Genoway stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Genoway over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genoway stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genoway's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Genoway Price |
|---|---|
| 9/4/2026 | 2.48 EUR |
| 9/3/2026 | 2.50 EUR |
| 9/2/2026 | 2.50 EUR |
| 9/1/2026 | 2.46 EUR |
| 8/31/2026 | 2.48 EUR |
| 8/28/2026 | 2.47 EUR |
| 8/27/2026 | 2.45 EUR |
| 8/26/2026 | 2.45 EUR |
| 8/25/2026 | 2.46 EUR |
| 8/24/2026 | 2.48 EUR |
| 8/21/2026 | 2.46 EUR |
| 8/20/2026 | 2.45 EUR |
| 8/19/2026 | 2.45 EUR |
| 8/18/2026 | 2.45 EUR |
| 8/17/2026 | 2.45 EUR |
| 8/14/2026 | 2.48 EUR |
| 8/13/2026 | 2.48 EUR |
| 8/12/2026 | 2.48 EUR |
| 8/11/2026 | 2.50 EUR |
| 8/10/2026 | 2.50 EUR |
| 8/7/2026 | 2.51 EUR |
| 8/6/2026 | 2.50 EUR |
| 8/5/2026 | 2.47 EUR |
| 8/4/2026 | 2.49 EUR |
| 7/31/2026 | 2.44 EUR |
| 7/30/2026 | 2.49 EUR |
| 7/29/2026 | 2.48 EUR |
| 7/28/2026 | 2.49 EUR |
| 7/27/2026 | 2.50 EUR |
| 7/24/2026 | 2.48 EUR |
Genoway Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Genoway Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEk EUR |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 9.00 | 9.00 | 10.00 | 11.00 | 13.00 | 14.00 | 14.00 | 11.00 | 14.00 | 17.00 | 20.00 | 22.00 | 20.00 | 26.00 | 32.00 |
| 14.29 | 12.50 | – | 11.11 | 10.00 | 18.18 | 7.69 | – | -21.43 | 27.27 | 21.43 | 17.65 | 10.00 | -9.09 | 30.00 | 23.08 |
| 87.50 | 55.56 | 55.56 | 50.00 | 54.55 | 53.85 | 57.14 | 57.14 | -18.18 | -21.43 | -5.88 | 90.00 | -4.55 | 50.00 | 50.00 | 50.00 |
| 7.00 | 5.00 | 5.00 | 5.00 | 6.00 | 7.00 | 8.00 | 8.00 | -2.00 | -3.00 | -1.00 | 18.00 | -1.00 | 10.00 | 13.00 | 16.00 |
| – | – | – | – | – | – | – | – | -3.00 | -4.00 | – | 2.00 | 1.00 | – | – | 1.00 |
| – | – | – | – | – | – | – | – | -27.27 | -28.57 | – | 10.00 | 4.55 | – | – | 3.13 |
| – | – | – | – | – | 1,000.00 | – | -1,000.00 | – | – | – | 1,000.00 | 1,000.00 | – | – | – |
| 5.90 | 5.91 | 5.94 | 5.95 | 5.95 | 5.83 | 5.97 | 5.86 | 6.78 | 8.82 | 8.82 | 8.84 | 9.85 | 12.46 | 12.46 | 12.46 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Genoway generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genoway retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genoway's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Genoway has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genoway's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Genoway stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Genoway Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Genoway business model & stock analysis
Genoway SWOT Analysis
Strengths
Genoway SA has a strong reputation in the biotechnology industry.
The company has a talented and experienced team of researchers and scientists.
Genoway SA offers a wide range of genetically engineered models and services.
The company has a robust intellectual property portfolio.
Genoway SA has a global presence and serves clients in multiple countries.
Weaknesses
The company heavily relies on a few key clients, making it vulnerable to client-specific risks.
Genoway SA has higher production costs compared to some competitors.
The company may face regulatory challenges in certain markets.
Genoway SA's product and service offerings may be affected by rapid technological advancements.
Opportunities
The increasing demand for genetically modified organisms (GMOs) presents an opportunity for Genoway SA to expand its market share.
Collaboration with pharmaceutical and biotechnology companies can lead to new product development opportunities.
Genoway SA can leverage its expertise to enter new geographical markets.
The company can explore partnerships with academic institutions and research organizations.
Threats
Intense competition from established players and emerging startups can pose a threat to Genoway SA's market position.
Increased regulations and potential ethical concerns regarding GMOs can impact the company's operations.
Economic downturns or fluctuations can lead to a decrease in customer spending on biotechnology services.
Technological advancements by competitors may outpace Genoway SA's innovations.
Genoway Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Genoway historical P/E ratio, EBIT multiple, and P/S ratio
Genoway annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Genoway shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Genoway forecasts and price targets in September 2026
Analyst Price Targets 2026Genoway shareholder structure
| % | Name |
|---|---|
16.27163% | |
11.34991% | |
6.81753% |
Genoway Beneficial Ownership Filings (SEC 13D/G)
Genoway Executives and Management Board
6 members · 0 % women
Management
Dr. Alexandre Fraichard
Chief Executive Officer · since 1999
Board of Directors
Mr. Benjamin Bruneau
Financial and Administrative Director
Mr. Christian Grenier
Chairman of the Board · since 2014
Mr. Laurent Fraisse
Director
Mr. Robert Leon
Director - Representative of Finoway · since 2012
Mr. Andre Tartar
Director
Frequently asked questions about Genoway
The business model of Genoway SA revolves around the provision of customized preclinical research models and associated services to the biopharmaceutical industry. As a leading provider in the field of genetically modified laboratory mice, Genoway SA specializes in the design, development, and production of highly specialized animal models that mimic human diseases, aiding researchers in the development of new treatments and therapies. By leveraging their expertise in genetic engineering and molecular biology, Genoway SA offers a range of services such as model creation, breeding, and colony management to facilitate efficient and targeted research.
Genoway SA is primarily active in the biotechnology industry.
The main competitors of Genoway SA in the market include companies such as Charles River Laboratories, Taconic Biosciences, and Transposagen Biopharmaceuticals. These companies also provide services in the field of genetically modified models and related research solutions. However, Genoway SA stands out with its innovative technology and extensive experience in the industry. As a leading provider of custom-made research models and associated services, Genoway SA offers unique solutions tailored to the specific needs of their clients. Their commitment to quality, reliability, and customer satisfaction sets them apart from their competitors in the market.
Genoway SA, a leading company in the field of custom genetically modified mouse models, has an impressive history and background. Founded in 1999, Genoway SA has continuously contributed to the advancement of scientific research through its innovative genomic engineering solutions. With a strong focus on creating efficient research models, the company has established itself as a global leader in the field. Genoway SA's expertise and commitment to excellence have enabled numerous breakthroughs in drug discovery, preclinical evaluation, and therapeutic development. With a dedicated team of experts, Genoway SA consistently strives to provide cutting-edge mouse models that revolutionize the biomedical research community. Trust Genoway SA for your research needs and experience their unparalleled commitment to excellence.
Genoway SA has achieved several significant milestones in its company history. These milestones include successfully establishing itself as a leading provider of customized research models and related services. Additionally, the company has built a strong reputation for its expertise in genetic engineering and the creation of genetically modified animal models. Genoway SA has also expanded its global presence by establishing collaborations and partnerships with renowned academic institutions and industry leaders. These achievements have cemented Genoway SA's position as a key player in the field of genetic research and development, driving innovation and advancements in various scientific disciplines.
Genoway SA is primarily present in Europe, with a strong presence in France. As a leading biotechnology company, Genoway SA operates globally with a focus on providing innovative animal models and research services. Their extensive network and collaborations span across various regions, including Europe, North America, and Asia. With their commitment to research and development, Genoway SA continues to expand its presence internationally, delivering cutting-edge solutions to clients worldwide.
Genoway SA is a leading company that represents values and a corporate philosophy centered around innovation, collaboration, and scientific expertise. With a strong focus on providing cutting-edge solutions in the field of genetically modified organisms (GMOs) for the pharmaceutical and biotechnology industries, Genoway SA aims to revolutionize drug discovery and development. Their commitment to excellence, integrity, and sustainability is reflected in every aspect of their operations. By leveraging advanced gene editing technologies and a multidisciplinary approach, Genoway SA strives to contribute to the advancement of life science research and to address critical healthcare challenges globally.
Analysts currently set an average price target of 6.02 EUR for the Genoway stock (median: 6.02 EUR), implying +142.7 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Genoway stock: 8 recommend buying, 1 holding and 0 selling.
The Genoway share (ALGEN.PA) is listed on 4 stock exchanges, including: Frankfurt (JEH.F), München (JEH.MU), Paris (ALGEN.PA).
Genoway SA is a leading biotech company based in Lyon, France, specializing in the development and sale of genetically modified animal models for biomedical research. The company offers customized genetic services to academic and industrial customers and is known for its expertise and innovation in its offerings. Genoway specializes in the production of transgenic and knockout mouse models using gene editing technologies such as CRISPR/Cas9 to selectively modify or disable specific genes. The products and services of Genoway include the delivery of fully customized animal models for research. The company offers a variety of product lines tailored to specific research needs, such as oncology, immunology, and neurology. The various product lines of Genoway include genetically modified mice, rats, and rabbits. Mice are the most commonly used animals for medical research, and the company specializes in developing models for cancer, inflammation, autoimmune diseases, and infectious diseases. Genoway's products offer numerous benefits by simulating the phenotypic effect of gene mutations observed in many human diseases. This allows scientists to study the effects of drugs, therapies, and other interventions on these specific diseases. In addition, genetically modified animals reduce the extent of animal research, contributing to the optimization of research outcomes. The company has also developed a specialized analysis service concept that allows researchers to quickly and easily test their genetically modified animal models for gene mutations responsible for the desired disease characteristics. Genoway has also gained a high level of recognition through its collaborations with various research institutions and pharmaceutical companies. This has enabled the company to position itself as a leading provider of customized genetic services in the biotech industry. In summary, Genoway's business model aims to meet the needs of customers in the biotech industry by offering a wide range of customized products and services. By utilizing gene editing technologies and focusing on specific animal models for medical research, the company has developed innovative and high-quality solutions that are widely adopted and accepted in the biotech industry.
The expected revenue of Genoway is 26.27 M EUR. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Genoway.
The P/E ratio cannot be calculated for Genoway at the moment.
The price-to-sales ratio (P/S) of Genoway is currently 1.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genoway stock.
The Eulerpool Quality Score for Genoway is 4/10.
The ISIN of Genoway is FR0004053510. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genoway is A0MRJ4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genoway is ALGEN.PA. The ticker symbol is used to trade Genoway shares on the stock exchange.
Genoway paid dividends every year for the past 0 years.
Genoway is assigned to the 'Health' sector.
The dividends of Genoway are distributed in EUR.
Genoway stock
Genoway Ticker
Genoway FIGI
All fundamentals and in-depth analysis of Genoway
Our stock analysis for Genoway stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genoway. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.